Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary systemic vasculitis: treatment of difficult cases.

R Foster1, E Rosenthal, S Marques

  • 1Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK.

Lupus
|April 26, 2006
PubMed
Summary

Systemic necrotizing vasculitides are serious diseases with high mortality. This review explores alternative treatments for patients unresponsive or intolerant to standard therapies, including those with antiphospholipid antibodies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal presentation of fetal bradycardia and long QT syndrome.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2026
Same author

Major barriers and facilitators of care for patients with infectious complications of opioid use disorder: A multi-site, qualitative analysis of expert stakeholders from the CHOICE protocol.

Journal of substance use and addiction treatment·2025
Same author

A patient with multiple sclerosis successfully treated with tofacitinib for rheumatoid arthritis.

Scandinavian journal of rheumatology·2025
Same author

Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2022
Same author

Partial Ribosomal Nontranscribed Spacer Sequences Distinguish Rhagoletis zephyria (Diptera: Tephritidae) From the Apple Maggot, R. pomonella.

Journal of economic entomology·2022
Same author

[Characteristics of patients admitted from emergency units in 18 internal medicine departments and organisation of these departments: A cross sectional study from SNFMI (SiFMI study group) in 2015].

La Revue de medecine interne·2020

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Primary systemic necrotizing vasculitides (SNVs) are severe autoimmune diseases with high mortality if untreated.
  • Conventional treatments like high-dose steroids and cyclophosphamide are effective for many SNVs but cause significant morbidity and treatment failure in a substantial patient subset.
  • Patients with SNVs and antiphospholipid antibodies present unique diagnostic and therapeutic challenges.

Purpose of the Study:

  • To review and discuss alternative and emerging treatment options for SNVs.
  • To explore the specific challenges and management strategies for SNVs associated with antiphospholipid antibodies.
  • To recommend screening for antiphospholipid antibodies in all patients diagnosed with systemic vasculitis.

Main Methods:

Related Experiment Videos

  • Literature review of existing studies on SNVs.
  • Discussion of current and novel therapeutic approaches.
  • Analysis of the role of antiphospholipid antibodies in SNVs.

Main Results:

  • A significant proportion of patients with SNVs experience morbidity from conventional treatments or are refractory to them.
  • Antiphospholipid antibodies represent a distinct subgroup of SNVs requiring tailored management.
  • Evidence suggests a potential benefit from screening for antiphospholipid antibodies.

Conclusions:

  • Alternative and emerging therapies are crucial for SNV patients who cannot tolerate or fail conventional treatments.
  • Screening for antiphospholipid antibodies in all systemic vasculitis patients is warranted for improved diagnosis and treatment.
  • Further research into novel therapeutic strategies for refractory SNVs and those with antiphospholipid antibodies is needed.